These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24281621)

  • 1. High blood pressure (hypertension) may influence the results of clinical trials for scar and keloid treatments.
    Ogawa R
    Plast Reconstr Surg; 2013 Dec; 132(6):1074e-1075e. PubMed ID: 24281621
    [No Abstract]   [Full Text] [Related]  

  • 2. Wound healing: from embryos to adults and back again.
    Tredget EE; Ding J
    Lancet; 2009 Apr; 373(9671):1226-8. PubMed ID: 19362658
    [No Abstract]   [Full Text] [Related]  

  • 3. Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
    Occleston NL; Fairlamb D; Hutchison J; O'Kane S; Ferguson MW
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1231-9. PubMed ID: 19604123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scar prevention and remodeling: a review of the medical, surgical, topical and light treatment approaches.
    Kerwin LY; El Tal AK; Stiff MA; Fakhouri TM
    Int J Dermatol; 2014 Aug; 53(8):922-36. PubMed ID: 24697346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial.
    Bush J; Duncan JAL; Bond JS; Durani P; So K; Mason T; O'Kane S; Ferguson MWJ
    Plast Reconstr Surg; 2010 Nov; 126(5):1604-1615. PubMed ID: 21042116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor β3 for the prevention of vocal fold scarring.
    Ohno S; Hirano S; Kanemaru S; Kitani Y; Kojima T; Ishikawa S; Mizuta M; Tateya I; Nakamura T; Ito J
    Laryngoscope; 2012 Mar; 122(3):583-9. PubMed ID: 22252900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach for the prophylactic improvement of surgical scarring: avotermin (TGF beta 3).
    Young VL; Bush J; O'Kane S
    Clin Plast Surg; 2009 Apr; 36(2):307-13, viii. PubMed ID: 19309655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II clinical trial of avotermin versus placebo for scar improvement.
    McCollum PT; Bush JA; James G; Mason T; O'Kane S; McCollum C; Krievins D; Shiralkar S; Ferguson MW
    Br J Surg; 2011 Jul; 98(7):925-34. PubMed ID: 21618480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial.
    So K; McGrouther DA; Bush JA; Durani P; Taylor L; Skotny G; Mason T; Metcalfe A; O'Kane S; Ferguson MWJ
    Plast Reconstr Surg; 2011 Jul; 128(1):163-172. PubMed ID: 21701333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scar revision review.
    Thomas JR; Somenek M
    Arch Facial Plast Surg; 2012; 14(3):162-74. PubMed ID: 22801760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis.
    Lichtman MK; Otero-Vinas M; Falanga V
    Wound Repair Regen; 2016 Mar; 24(2):215-22. PubMed ID: 26704519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
    Ferguson MW; Duncan J; Bond J; Bush J; Durani P; So K; Taylor L; Chantrey J; Mason T; James G; Laverty H; Occleston NL; Sattar A; Ludlow A; O'Kane S
    Lancet; 2009 Apr; 373(9671):1264-74. PubMed ID: 19362676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Techniques for Optimizing Surgical Scars, Part 2: Hypertrophic Scars and Keloids.
    Potter K; Konda S; Ren VZ; Wang AL; Srinivasan A; Chilukuri S
    Skinmed; 2017; 15(6):451-456. PubMed ID: 29282183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cementogenesis and periodontal ligament regeneration by recombinant human transforming growth factor-beta3 in Matrigel with rectus abdominis responding cells.
    Ripamonti U; Parak R; Petit JC
    J Periodontal Res; 2009 Feb; 44(1):81-7. PubMed ID: 18973524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical.
    Occleston NL; Laverty HG; O'Kane S; Ferguson MW
    J Biomater Sci Polym Ed; 2008; 19(8):1047-63. PubMed ID: 18644230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scar wars.
    Ferguson MW
    Br Dent J; 2002 Apr; 192(8):475. PubMed ID: 12014697
    [No Abstract]   [Full Text] [Related]  

  • 17. Surgical principles for achieving a functional and cosmetically acceptable scar.
    Pérez-Bustillo A; González-Sixto B; Rodríguez-Prieto MA
    Actas Dermosifiliogr; 2013 Jan; 104(1):17-28. PubMed ID: 22677123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Save the skin and improve the scar: a simple technique to minimize the scar from a temporary stoma.
    Keating J; Kelly EW; Hunt I
    Dis Colon Rectum; 2003 Oct; 46(10):1428-9. PubMed ID: 14530688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow derived mesenchymal stem cells inhibit the proliferative and profibrotic phenotype of hypertrophic scar fibroblasts and keloid fibroblasts through paracrine signaling.
    Fang F; Huang RL; Zheng Y; Liu M; Huo R
    J Dermatol Sci; 2016 Aug; 83(2):95-105. PubMed ID: 27211019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scar revision.
    Onizuka T
    Aesthetic Plast Surg; 1982; 6(2):85-9. PubMed ID: 7124550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.